Seelos Therapeutics, Inc. (NASDAQ:SEEL) has made a 150% comeback from a 12-month low price of $1.32. It was seen 3.77% higher, changing the price to $3.3, when the closing bell rang on 4/8/2019. At a recent session, the prices were hovering between $3.0601 and $3.44. This company shares are -54.55% up from its target price of $1.5 and the current market capitalization stands at $61.54M. The recent change has given its price a 4.44% lead over SMA 50 and -81.03% deficit over its 52-week high. The stock witnessed -2.65% declines, -57.69% declines and -66.1% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found SEEL’s volatility during a week at 8.52% and during a month it has been found around 16.63%.Seelos Therapeutics, Inc. (SEEL) Top Holders
Institutional investors currently hold around $1 million or 14% in SEEL stock. Look at its top three institutional owners: Geode Capital Management, Llc owns $726 thousand in Seelos Therapeutics, Inc., which represents roughly 1.18% of the company’s market cap and approximately 72.6% of the institutional ownership. Similar statistics are true for the second largest owner, Armistice Capital, Llc, which owns 153,318 shares of the stock are valued at $488 thousand. The third largest holder is Renaissance Technologies Llc, which currently holds $20 thousand worth of this stock and that ownership represents nearly 0.03% of its market capitalization.
At the end of December reporting period, 7 institutional holders increased their position in Seelos Therapeutics, Inc. (NASDAQ:SEEL) by some 232,584 shares, 7 decreased positions by 7,489 and 19 held positions by 171,694. That puts total institutional holdings at 411,767 shares, according to SEC filings. The stock grabbed 6 new institutional investments totaling 1,224 shares while 4 institutional investors sold out their entire positions totaling 4,765 shares.
Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing technologies and therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company is focused on neurological and psychiatric disorders, including orphan indications. Its lead programs are SLS-002, an intranasal racemic ketamine for the treatment of suicidality in post-traumatic stress disorder and in depressive disorder; and SLS-006, a partial dopamine agonist for monotherapy in early stage Parkinson’s disease patients.